Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Healthcare Times Guadeloupe.
Press releases published on June 20, 2025
Onco360 Has Been Selected as a National Specialty Pharmacy Partner for QINLOCK® (ripretinib)
GlobeNewswire
·
June 20, 2025
LOUISVILLE, Ky., June 20, 2025 (GLOBE NEWSWIRE) -- Onco360®, the nation’s leading independent specialty pharmacy, has been selected as a pharmacy partner by Deciphera Pharmaceuticals, LLC for QINLOCK® (ripretinib), which has been approved by the U.S. Food …
GoPath Diagnostics Announces Launch of DiabetesNow: A Genetic Test Panel Designed to Clarify Diabetes Diagnosis
GlobeNewswire
·
June 20, 2025
Buffalo Grove, IL, June 20, 2025 (GLOBE NEWSWIRE) -- A More Complete Genetic View of Diabetes DiabetesNow combines testing for 16 genes associated with monogenic forms of diabetes—including MODY, neonatal, syndromic, and mitochondrial types—with polygenic …
CHMP recommends third indication for darolutamide for patients with advanced prostate cancer
GlobeNewswire
·
June 20, 2025
ORION CORPORATION PRESS RELEASE 20 JUNE 2025 at 13.30 EEST CHMP recommends third indication for darolutamide for patients with advanced prostate cancer CHMP adopts positive opinion for the marketing authorisation of darolutamide in combination …
Euroopan lääkeviraston ihmislääkekomitealta (CHMP) myönteinen lausunto darolutamidin kolmannelle käyttöaiheelle edennyttä eturauhassyöpää sairastavien potilaiden hoidossa
GlobeNewswire
·
June 20, 2025
ORION OYJ LEHDISTÖTIEDOTE 20.6.2025 klo 13.30 Euroopan lääkeviraston ihmislääkekomitealta (CHMP) myönteinen lausunto darolutamidin kolmannelle käyttöaiheelle edennyttä eturauhassyöpää sairastavien potilaiden hoidossa CHMP suosittaa myyntiluvan …
Ipsen receives positive CHMP opinion for Cabometyx® in previously treated advanced neuroendocrine tumors
GlobeNewswire
·
June 20, 2025
If approved, Cabometyx® would be the first and only systemic therapy approved in the European Union for previously treated neuroendocrine tumors, regardless of tumor site, grade or previous non-somatostatin analogue-based systemic therapy1,2 Recommendation …
Ipsen reçoit un avis positif du CHMP pour Cabometyx® dans les tumeurs neuroendocrines avancées précédemment traitées
GlobeNewswire
·
June 20, 2025
S’il est approuvé, Cabometyx® sera le premier et unique traitement systémique autorisé dans l’Union européenne pour les tumeurs neuroendocrines précédemment traitées, indépendamment de la localisation de la tumeur, de sa gravité et de l’administration ou …
Dupixent® (dupilumab) Approved in the U.S. as the Only Targeted Medicine to Treat Patients with Bullous Pemphigoid (BP)
GlobeNewswire
·
June 20, 2025
Approval based on pivotal results showing improvements in sustained disease remission and reductions in itch and oral corticosteroid use compared to placebo in adults with BP BP is a chronic, debilitating and relapsing rare skin disease affecting …
HealthRX Expands Telehealth Website Experience to Include GLP-1 Weight Loss Solutions, Prescription Access, and 24/7 Wellness Support
GlobeNewswire
·
June 20, 2025
BROOKLYN, June 19, 2025 (GLOBE NEWSWIRE) -- HealthRX, a digital health platform serving adults across the United States, has announced an expanded online experience designed to support weight management and long-term wellness through a suite of integrated …
Telix Theranostic Programs and Satellite Symposia on Innovation in PSMA and CAIX Imaging Featured at SNMMI 2025
GlobeNewswire
·
June 20, 2025
MELBOURNE, Australia and INDIANAPOLIS, June 20, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”, “the Company”) today announces five abstract presentations and two satellite symposia featuring its developmental …